MedTrace Logo

Atacicept in Multiple Glomerular Diseases

NCT06983028 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-01-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of atacicept in adult and adolescent participants and to measure the effect in reducing proteinuria and preserving renal function.

Conditions

  • pMN
  • IgAN
  • Nephrotic Syndrome
  • MCD
  • FSGS

Interventions

DRUG

Atacicept

Atacicept 150 mg SC QW via pre-filled syringe

Sponsors & Collaborators

  • Vera Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Pam Winterberg · Vera Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-07
Primary Completion
2027-11-30
Completion
2027-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06983028 on ClinicalTrials.gov